Scarica l'app Stockscreener
1.16
2.65%
0.03
Dopo l'orario di chiusura:
1.18
0.02
+1.72%
Precedente Chiudi:
$1.13
Aprire:
$1.13
Volume 24 ore:
55,113
Relative Volume:
0.34
Capitalizzazione di mercato:
$18.65M
Reddito:
-
Utile/perdita netta:
$-11.23M
Rapporto P/E:
-1.4599
EPS:
-0.7946
Flusso di cassa netto:
$-14.83M
1 W Prestazione:
+8.41%
1M Prestazione:
+16.58%
6M Prestazione:
-28.40%
1 anno Prestazione:
+31.28%
Intervallo 1D:
$1.12
$1.19
Intervallo di 1 settimana:
$1.01
$1.19
Portata 52W:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.16 | 18.65M | 0 | -11.23M | -14.83M | -0.7946 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation - Minichart
Allarity Therapeutics posts $320k revenue, $11.2M net loss and $14.7M year-end cash (2025) - TradingView
Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan
ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - ca.finance.yahoo.com
TON Strategy Company (VERB) Reports FY2025 Earnings - AlphaStreet
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Investing News Network
Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet
Purple Innovation, Inc. (PRPL) Reports Q4 Earnings - AlphaStreet
Allarity Therapeutics reports full year 2025 financial results and corporate progress - marketscreener.com
Market Catalysts: Is Allarity Therapeutics Inc stock forming a cup and handleWeekly Investment Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress - TradingView
Cancer drug gets FDA Fast Track as Allarity says cash lasts to 2028 - Stock Titan
Stenoparib push: Allarity Therapeutics (NASDAQ: ALLR) reshapes cancer pipeline - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2% - Defense World
Shorts Report: Can Allarity Therapeutics Inc disrupt its industry2026 Market Trends & Consistent Return Strategy Ideas - baoquankhu1.vn
Former Allarity Executive Winnows SEC’s FDA Approval Scheme Suit - Bloomberg Law News
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday - Defense World
Volume Summary: Will Allarity Therapeutics Inc stock recover after earningsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Pharma News: Can Allarity Therapeutics Inc expand its profit margins2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Allarity Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | C6D | US0167441049 - marketscreener.com
Aug Spikes: Whats the analyst consensus on Allarity Therapeutics IncGlobal Markets & AI Driven Stock Reports - baoquankhu1.vn
Inflation Data: Can Allarity Therapeutics Inc disrupt its industry2026 Technicals & Technical Entry and Exit Tips - baoquankhu1.vn
MACD Signal: Can Allarity Therapeutics Inc expand its profit marginsTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - minichart.com.sg
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway By Investing.com - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity secures $20M debt financing to extend cash runway - Investing.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
ALLR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
First patients dosed in VA-funded stenoparib trial for lung cancer - Investing.com Australia
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):